Wilex gives clinical update at Q1

Country

Germany

Wilex AG expects to file for the registration of its experimental antibody for renal cell carcinoma, girentuximab, in the US and Europe during the first half of 2013. Data from a pivotal trial of the drug are expected in the fourth quarter of this year.